XNPT Share Price

Open 7.03 Change Price %
High 7.07 1 Day 0.05 0.71
Low 7.02 1 Week 0.00 0.00
Close 7.07 1 Month 0.00 0.00
Volume 2615875 1 Year 2.67 60.68
52 Week High 7.10
52 Week Low 3.90
XNPT Important Levels
Resistance 2 7.12
Resistance 1 7.10
Pivot 7.05
Support 1 7.04
Support 2 7.02
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
STRT 32.15 30.16%
WRES 0.09 28.57%
TBBK 6.45 27.47%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
EHTH 14.18 20.78%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
ROSE 10.35 -48.20%
ROSE 10.35 -48.20%
DVOX 0.05 -44.44%
More..

XenoPort, Inc. (NASDAQ: XNPT)

XNPT Technical Analysis 5
As on 5th Jul 2016 XNPT Share Price closed @ 7.07 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.44 & Strong Buy for SHORT-TERM with Stoploss of 5.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
XNPT Target for April
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
XNPT Other Details
Segment EQ
Market Capital 330802368.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.xenoport.com
XNPT Address
XNPT
3410 Central Expressway
Santa Clara, CA 95051
United States
Phone: 408-616-7200
Interactive Technical Analysis Chart XenoPort, Inc. ( XNPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on XenoPort, Inc.
XNPT Business Profile
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders. The product candidates are prodrugs that are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The Company focuses its development and commercialization efforts on treatments of diseases with unmet medical needs, with an emphasis on central nervous system disorders. The products are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. In April 2011, the United States Food and Drug Administration (FDA), approved the Company�s first product, known in the United States as Horizant (gabapentin enacarbil) Extended-Release Tablets, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults.